India BSE NSE Trading Suspension Orders — June 02, 2026

International credit rating upgraded to 'BB-' (Stable) by S&P, following upgrades from CRISIL, CARE, and ICRA since April 2026. This series of upgrades is expected to lower borrowing costs and support growth, reflecting stronger capitalization post-IHC investment.

Q4 FY26 PAT surged +64% YoY to ₹4,271 Cr, significantly outperforming the modest +10% revenue growth, indicating strong operating leverage and margin expansion.

Full-year FY26 revenue declined -2% YoY to ₹57,865 Cr and EBITDA fell -2% YoY to ₹23,431 Cr, signaling a slowdown in the core business despite the strong Q4.

Net debt increased sharply to ₹45,022 Cr from ₹31,023 Cr in FY25, a +45% YoY jump, raising concerns about leverage despite the growth pipeline.

Received USFDA approval for Mycophenolate Mofetil, targeting a ~US$30 million U.S. market. This is a new product approval that supports the company's growth strategy in international markets.

Completed acquisition of an additional 20% stake in Aggne Global Inc. ahead of the June 5 deadline, demonstrating execution efficiency and commitment to its acquisition strategy.

Credit ratings reaffirmed at [ICRA]AA+ (Stable) for long-term and [ICRA]A1+ for short-term instruments, with a new rating for ₹300 Cr NCDs. The stable outlook indicates no near-term credit deterioration.

Incorporation of a fintech distribution subsidiary signals a strategic pivot into financial services, but with no financial details disclosed, the near-term impact is minimal.

Appointment of B S R & Co. LLP as new statutory auditors and KPMG for US SEC filings is a routine mandatory rotation, but the 10-minute board meeting duration suggests a non-contentious process.

Full-year FY26 revenue fell -2% YoY to ₹57,865 Cr, a red flag given the company's aggressive growth narrative and the expected rise in India's power demand.

Net debt increased +45% YoY to ₹45,022 Cr, significantly outpacing revenue growth. This leverage could pressure margins if interest rates rise or power demand softens.

Full-year EBITDA declined -2% YoY, indicating that operational efficiency is not keeping pace with capacity expansion.

The company's own investor presentation shows a stark contrast between a strong Q4 and a weak full year, suggesting potential lumpiness in earnings or one-off benefits in Q4.

The fintech subsidiary is a new venture with no disclosed financials or performance metrics, carrying execution risk in a competitive fintech space.

While mandatory, the change from Deloitte to B S R & Co. LLP and KPMG could lead to temporary audit process disruptions or changes in accounting treatments.

The U.S. market for the approved drug is estimated at ~US$30 million, which is relatively small. Revenue contribution may be limited unless the company captures significant market share.

The S&P upgrade to 'BB-' (Stable) is a strong catalyst. Expect lower borrowing costs, improved access to capital markets, and potential re-rating. The stock could benefit as the market prices in the improved credit profile.

The +64% YoY PAT growth in Q4 FY26, despite a full-year decline, suggests a potential turnaround. If this momentum continues into FY27, the stock could see significant upside.

With a locked-in capacity of 23.7 GW (vs 18.3 GW operating), the company has a clear growth pipeline. The 100% land and BTG availability de-risks execution.

The USFDA approval for a transplant drug opens a new revenue stream. With the U.S. market at ~US$30 million, even a modest market share could add 5-10% to the company's top line.

The reaffirmation of AA+ ratings with a stable outlook provides a floor for the stock. Investors seeking safety in the auto sector can consider this as a low-risk, stable dividend play.

The early completion of the Aggne Global stake purchase signals strong integration capabilities. Watch for margin improvement from the acquisition in the coming quarters.

While early, the fintech subsidiary could unlock a new growth vector. If Delhivery leverages its logistics network for financial distribution, it could create a unique B2B fintech model.

Sammaan Capital's multiple rating upgrades contrast with Adani Power's rising debt. This highlights a divergence where well-capitalized NBFCs are benefiting from improved credit access, while capital-intensive infrastructure players face leverage risks. Investors should favor companies with strong credit profiles. [IMPLICATION: Favor Sammaan Capital over Adani Power on credit quality]

Adani Power's data shows a classic 'beat and miss' pattern. While Q4 FY26 was strong, the full-year decline suggests structural headwinds (e.g., coal costs, regulatory changes). Investors should look for consistent full-year growth rather than relying on a single quarter. [IMPLICATION: Be cautious on power stocks with lumpy earnings]

Concord Biotech's approval for a niche transplant drug (US$30M market) is a micro-cap opportunity. This theme suggests that smaller pharma companies with focused ANDA pipelines can generate alpha, even in small markets. [IMPLICATION: Look for niche FDA approvals in small-cap pharma]

Ashok Leyland's reaffirmed AA+ rating indicates a mature, stable business. In a volatile auto cycle, companies with strong balance sheets and stable credit profiles are safer bets. [IMPLICATION: Prefer auto stocks with investment-grade ratings]

Delhivery's fintech subsidiary incorporation is a low-materiality event but signals a broader trend of logistics companies moving into financial services (e.g., Shiprocket, Delhivery). This could be a long-term value driver if executed well. [IMPLICATION: Monitor Delhivery's fintech progress for a potential re-rating]

Q1 FY27 results (expected mid-August 2026) to see if Q4 FY26 momentum continues. Watch for debt reduction plans and any guidance on FY27 revenue/EBITDA.

Upcoming Q1 FY27 earnings call (likely July 2026) to quantify the impact of lower borrowing costs from the rating upgrades. Watch for any NIM expansion guidance.

Commercial launch timeline for the Mycophenolate Mofetil product in the U.S. market. Watch for any partnership announcements or initial sales data.

Q1 FY27 results (expected July 2026) to see the financial impact of the Aggne Global acquisition. Watch for any margin accretion from the deal.

Any further disclosures on the fintech subsidiary's business plan, capital infusion, or initial operations. Watch for any partnership announcements in the fintech space.

Any change in the 'Stable' outlook from ICRA. Watch for any debt-funded expansion plans that could pressure the rating.

Shareholder meeting date for the auditor appointment approval (expected before the 81st AGM in 2027). Watch for any dissent from large shareholders.